India's listed new-age technology companies lost a combined $3.6 billion in market value this week, but 28 of 65 stocks rose, led by Capillary Technologies and Zelio E-Mobility, as investors rewarded fundraising and punished regulatory risk.
The United Forum of Bank Unions says its three-day strike from September 28 to 30 will go ahead after talks with the finance ministry and the Indian Banks' Association failed to produce a timeline for a five-day banking week.
India's benchmark indices ended lower for a seventh consecutive week, with the Nifty down about 5.8% over the run, as record foreign outflows, US Treasury yields at 2007 highs and crude above $100 weighed on sentiment despite a Friday rebound.
The IITM Unicorn Frontier Fund I has reached a first close of ₹450 crore towards a ₹1,000 crore target, and plans to back about 25 deep-tech startups in areas from defence and spacetech to semiconductors, robotics and climate technology.
Indian startups raised $203.4 million across 21 deals between September 21 and 25, more than three times the previous week's total, led by Ultraviolette's $85 million round and Ema's $77 million Series B.
Passengers and drivers in Ahmedabad and Gandhinagar allege that groups have stopped Uber and Rapido rides and pressured drivers to switch to the government-backed cooperative Bharat Taxi, raising questions about fair competition, passenger safety and driver livelihoods.
Aequs's board has approved a preferential issue of up to 2.8 crore warrants to its promoter group at ₹231.55 each, raising about ₹650 crore to build capacity across aerospace and consumer manufacturing, with ₹325 crore payable at allotment.
Private equity firm True North has reportedly picked up a 2–3% stake in adtech group InMobi for about $50–60 million, largely through secondary purchases, as the Bengaluru-founded company moves its domicile to India ahead of a planned public listing.
Buy&Ship, a Hong Kong cross-border e-commerce logistics company, is the first Hong Kong start-up admitted to the Tokyo Stock Exchange's Asia Startup Hub. The move puts a Tokyo listing on the table as Japan becomes central to its business.
Moderna shares reached a 52-week high on September 25, extending a rally driven by late-stage trial success for intismeran autogene, the individualised melanoma vaccine it is developing with Merck. Investors are now looking ahead to full data expected in late October.